The molecular technologies are based on a solid scientific foundation described in > 200 scientific publications including Science, Nature Genetics, Nature Biotechnology, Nature Methods and PNAS among others. The enabling technologies are continuously developed by leading scientists at Uppsala and Stockholm Universities and has to date formed the basis for four commercial companies, including Q-linea.
Our technology for infectious agents detection is based on highly specific padlock probes and C2CA isothermal nucleic acid amplification technology.
Major advantages of the technologies are substantially higher degree of multiplexing capability, as compared to PCR based techniques; it is suitable for random access type of analysis. Padlock probes have been shown to allow up to 20.000-plex measurements.
C2CA is a homogenous method of sequential rolling circle amplification steps (RCA). The long reaction product from a first round of RCA is cleaved into single copies of the template sequence by adding a restriction enzymes and an oligonucleotide that hybridizes to the product to form a duplex at the restriction site. With an excess of this added oligonucleotide, the cleavage product can be denatured and re-annealed to form circular structures that are closed by ligation. These circles can then be amplified using a second and third round of RCA. The use of C2CA and padlock probes have been shown to be useful for detection of bacteria and spores.
Detection and identification of pathogens in blood samples are challenging due to the strict requirements on specificity, sensitivity and time.
Using a combination of padlock probes and C2CA specific and sensitive pathogen identification directly in human blood can be achieved.
The high multiplexing level, enabled by the specificity of padlock probes, allow many different bacteria to be detected simultaneous without the problems of cross-reactivity seen with multiplexed PCR.